Can Light Therapy Help with Dementia?
The evidence is promising. This systematic review of studies from 1967 to 2020 found that photobiomodulation using red and near-infrared light showed positive effects on brain function in both pre-clinical models and early clinical studies of dementia, including Alzheimer’s disease.
Red light therapy, also known as low-level laser therapy (LLLT) or photobiomodulation (PBM), uses specific wavelengths of red and near-infrared light to promote healing and reduce inflammation.
Dementia, including Alzheimer’s disease, remains one of the greatest challenges in medicine. Current medications provide limited benefit, and there is no cure. Photobiomodulation (PBM), which uses red or near-infrared light delivered through the skull and sometimes intranasally, has emerged as a potential treatment approach. This systematic review compiled and analyzed all available research on PBM for dementia to determine where the evidence stands.
What the Research Shows
The review followed PRISMA guidelines and searched literature from 1967 to 2020 using keywords related to both photobiomodulation and dementia. The researchers carefully documented the light parameters used in each study, including wavelength, output power, energy density, treatment duration, total dose, continuous versus pulsed mode, and the number of treatment sessions. Of 36 included studies, 9 were in vitro, 17 were in animal models of dementia, and 10 were in dementia patients. All of them reported positive results. The clinical evidence is still thin. The 10 patient studies were small, some had no placebo group, and only a few used objective brain imaging.
Dr. Kumar’s Take
This is one of those areas where I feel a real sense of urgency. Current Alzheimer’s medications are marginally effective at best, and many come with significant side effects. PBM offers something fundamentally different. Instead of putting a chemical into the brain, it delivers energy in the form of light that the brain’s own mitochondria can use. The authors call the clinical evidence preliminary, and they found no adverse effects. Their conclusion is that larger clinical trials should be done as soon as possible, and I agree.
How Light Reaches the Brain
A common question is whether light can actually penetrate the skull. The answer is yes, but only a small fraction of the applied light gets through. Near-infrared light penetrates bone and tissue more effectively than visible red light. Some protocols also use intranasal delivery, where light is applied through the nasal cavity to reach areas of the brain that are closer to the surface through that route.
Practical Takeaways
- All 36 studies in this review reported positive results, but the 10 patient studies were small and early.
- Near-infrared light penetrates the skull better than visible red light.
- PBM is not a cure for dementia. Larger clinical trials are needed to show what it can do.
- Home-use transcranial PBM devices are becoming available, though clinical devices offer higher power.
FAQs
Can photobiomodulation prevent Alzheimer’s disease?
Prevention studies have not yet been conducted in humans. However, the biological mechanisms of PBM, such as reducing neuroinflammation, improving blood flow, and enhancing mitochondrial function, are all factors that contribute to brain health. It is plausible that regular PBM use could support brain health over time, but this has not been proven in clinical trials.
How often should someone with dementia use transcranial PBM?
There is no settled schedule yet. The review recorded the light settings and the number of treatment sessions in each study, and these differed from study to study. Larger trials are needed before a standard protocol can be set.
Is transcranial PBM safe for elderly patients?
Yes. The review found no serious adverse effects from transcranial PBM. The light does not heat the brain tissue to any meaningful degree, and it does not involve radiation. PBM is well tolerated by elderly patients, and the treatment itself is painless and noninvasive.
Bottom Line
This systematic review supports the potential of red light therapy as a treatment for dementia, including Alzheimer’s disease. The authors call the evidence of clinical benefit preliminary. The patient studies were small and some lacked placebo controls, but no adverse effects were reported, and the therapy is noninvasive and easy to use. Larger clinical trials are needed. For families facing a dementia diagnosis, PBM represents a promising supportive treatment worth exploring.
